HeartSciences EPS - Earnings per Share 2022-2026 | HSCS
HeartSciences eps - earnings per share from 2022 to 2026. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
| HeartSciences Annual EPS | |
|---|---|
| 2026 | $-3.48 |
| 2025 | $-9.34 |
| 2024 | $-18.74 |
| 2023 | $-80.00 |
| 2022 | $-145.00 |
| 2021 | $-74.00 |
| HeartSciences Quarterly EPS | |
|---|---|
| 2026-07-31 | $-0.86 |
| 2026-04-30 | $-0.42 |
| 2026-01-31 | $-0.63 |
| 2025-10-31 | $-0.85 |
| 2025-07-31 | $-1.58 |
| 2025-04-30 | $-1.86 |
| 2025-01-31 | $-2.57 |
| 2024-10-31 | $-2.27 |
| 2024-07-31 | $-2.64 |
| 2024-04-30 | $13.42 |
| 2024-01-31 | $-3.01 |
| 2023-10-31 | $-15.92 |
| 2023-07-31 | $-13.23 |
| 2023-04-30 | $-14.00 |
| 2023-01-31 | $-16.00 |
| 2022-10-31 | $-22.00 |
| 2022-07-31 | $-28.00 |
| 2022-04-30 | $-62.00 |
| 2022-01-31 | $-37.00 |
| 2021-10-31 | $-31.00 |
| 2021-07-31 | $-15.00 |
| 2021-04-30 | $0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $0.023B | $0.000B |
| Heart Test Laboratories, Inc. d/b/a HeartSciences is a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to expand and improve an ECG's clinical utility. Millions of ECGs are performed every week and the Company's objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. HeartSciences has one of the largest libraries of AI-ECG algorithms and is developing AI-ECG solutions to be made available on either a hardware agnostic cloud-based platform or its proprietary MyoVista? wavECG(TM) device, to help identify cardiovascular disease in any care setting worldwide in a manner to best suit different care providers. HeartSciences' first product candidate for FDA clearance, the MyoVista? wavECG(TM), or the MyoVista(R), is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Veeva Systems (VEEV) | United States | $42.703B | 42.61 |
| Tempus AI (TEM) | United States | $14.500B | 0.00 |
| 10x Genomics (TXG) | United States | $10.029B | 0.00 |
| Hinge Health (HNGE) | United States | $7.643B | 73.43 |
| Hims & Hers Health (HIMS) | United States | $6.507B | 0.00 |
| Doximity (DOCS) | United States | $4.736B | 29.20 |
| Heartflow (HTFL) | United States | $4.310B | 0.00 |
| IRhythm Holdings (IRTC) | United States | $3.684B | 242.93 |
| Privia Health (PRVA) | United States | $2.566B | 95.67 |
| Clover Health Investments (CLOV) | United States | $2.411B | 0.00 |
| Schrodinger (SDGR) | United States | $2.232B | 0.00 |
| Butterfly Network (BFLY) | United States | $2.120B | 0.00 |
| Inspire Medical Systems (INSP) | United States | $2.103B | 32.04 |
| Omnicell (OMCL) | United States | $1.484B | 21.18 |
| Azenta (AZTA) | United States | $1.473B | 80.07 |
| Enovis (ENOV) | United States | $1.027B | 5.31 |
| Talkspace (TALK) | United States | $0.879B | 0.00 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.716B | 0.00 |
| Phreesia (PHR) | United States | $0.638B | 34.27 |
| Fulgent Genetics (FLGT) | United States | $0.601B | 0.00 |
| Veradigm (MDRX) | United States | $0.587B | 0.00 |
| Claritev (CTEV) | United States | $0.538B | 0.00 |
| Carlsmed (CARL) | United States | $0.420B | 0.00 |
| Evolent Health (EVH) | United States | $0.415B | 0.00 |
| Senseonics Holdings (SENS) | United States | $0.394B | 0.00 |
| CapsoVision (CV) | United States | $0.317B | 0.00 |
| Standard BioTools (LAB) | United States | $0.287B | 0.00 |
| American Well (AMWL) | United States | $0.226B | 0.00 |
| KORU Medical Systems (KRMD) | United States | $0.148B | 0.00 |
| Health Catalyst (HCAT) | United States | $0.135B | 0.00 |
| Insight Molecular Diagnostics (IMDX) | United States | $0.129B | 0.00 |
| CareCloud (CCLD) | United States | $0.094B | 6.94 |
| Pulmonx (LUNG) | United States | $0.085B | 0.00 |
| Zepp Health (ZEPP) | Netherlands | $0.065B | 0.00 |
| Outset Medical (OM) | United States | $0.058B | 0.00 |
| Nyxoah SA (NYXH) | Belgium | $0.058B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.057B | 0.00 |
| EUDA Health Holdings (EUDA) | Singapore | $0.052B | 0.00 |
| Precipio (PRPO) | United States | $0.047B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.033B | 0.00 |
| 111 (YI) | China | $0.031B | 0.00 |
| Evaxion - (EVAX) | Denmark | $0.027B | 0.00 |
| HeartBeam (BEAT) | United States | $0.024B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.020B | 0.00 |
| DataMeds AI (MEDS) | United States | $0.015B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.011B | 0.00 |
| Lunai Bioworks (LNAI) | United States | $0.010B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.009B | 0.00 |
| ITonic Holdings (ITOC) | China | $0.005B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.003B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.001B | 0.00 |
| PROFUSA (PFSA) | United States | $0.001B | 0.00 |
| Zhongchao (ZCMD) | China | $0.001B | 0.00 |
| TruBridge (TBRG) | United States | $0.000B | 0.00 |